So I've had this epic run of very high risk prostate CA patients (Gleason 9-10, gross ECE and SVI, etc.) receiving RPs at the local NCI designated cancer center and then either never reaching undetectable or developing very early PSA relapse. I see many of these patients pre-surg, and I have found there is just nothing I can say that will dissuade them from getting a surgery once they're seen at this particular center. (This guy even has metastatic patients convinced they need prostatectomies). Is there any data (or trends in the data) to suggest we may be compromising survival in this cohort of very high risk patients by not doing early upfront ADT + Abi? Patients who relapse after surgery are generally getting ADT + XRT, so they miss out on this initial window of combined androgen blockade which clearly improves survival in the frankly metastatic setting. Any suggestion from data this matters in the non-metastatic, very high risk setting?